Health Care·Life Sciences Tools & Services·$7.8B
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $1.09 | N/A | -5.46% |
management commentary, guidance changes, and full analysis available with Pro.
| -5.46% |
Tone: Cautiously Optimistic
Overall, management remains cautiously optimistic about future performance. They emphasized their commitment to innovation and market expansion.
Management expressed confidence in long-term growth despite the EPS miss.
They highlighted ongoing investments in product development.
Bio Rad Laboratories reported an EPS of $1.09, slightly missing expectations, which contributed to a modest stock increase of 0.15%. The lack of revenue data and guidance may leave investors cautious, but management's focus on growth and innovation could support future performance. Overall, the market reacted positively despite the EPS miss.
AI-powered briefs, options data, and 20 quarters of history — everything you need before earnings.
No charge today · Auto-bills $8/mo after 7 days · Cancel anytime
TEXAS PACIFIC LAND C
Apr 30, 2012